Cheryl Rockman-Greenberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4665728/publications.pdf

Version: 2024-02-01

36 papers	895 citations	686830 13 h-index	476904 29 g-index
37 all docs	37 docs citations	37 times ranked	699 citing authors

#	Article	IF	Citations
1	An insight into the mechanisms of COVID-19, SARS-CoV2 infection severity concerning Î²-cell survival and cardiovascular conditions in diabetic patients. Molecular and Cellular Biochemistry, 2022, 477, 1681-1695.	1.4	15
2	Development of iPSC-based clinical trial selection platform for patients with ultrarare diseases. Science Advances, 2022, 8, eabl4370.	4.7	13
3	Establishment of a new human iPSC cell line (UOMi007-A) from a patient with Hypophosphatasia. Stem Cell Research, 2022, 63, 102839.	0.3	0
4	Neonatal hypoglycemia and the CPT1A P479L variant in term newborns: A retrospective cohort study of Inuit newborns from Kivalliq Nunavut. Paediatrics and Child Health, 2021, 26, 218-227.	0.3	4
5	Independent Registries Are Cost-Effective Tools to Provide Mandatory Postauthorization Surveillance for Orphan Medicinal Products. Value in Health, 2021, 24, 268-273.	0.1	7
6	Generation and Evaluation of Isogenic iPSC as a Source of Cell Replacement Therapies in Patients with Kearns Sayre Syndrome. Cells, 2021, 10, 568.	1.8	11
7	Human induced pluripotent stem cell (hiPSC) line UOMi006-A derived from PBMCs of a patient with Kearns-Sayre syndrome. Stem Cell Research, 2021, 53, 102355.	0.3	0
8	Generation of human induced pluripotent stem cell (hiPSC) line UOMi005-A from PBMCs of a patient with Kearns-Sayre syndrome. Stem Cell Research, 2021, 53, 102283.	0.3	5
9	Dental outcomes for children receiving StrensiqÂ® for Hypophosphatasia. Bone, 2021, 152, 116089.	1.4	8
10	Association of the CPT1A p.P479L Metabolic Gene Variant With Childhood Respiratory and Other Infectious Illness in Nunavut. Frontiers in Pediatrics, 2021, 9, 678553.	0.9	4
11	Generation of human induced pluripotent stem cell (hiPSC) line UOMi001-A from a patient with Leigh-like syndrome harbouring compound heterozygous variants in ECHS1 gene. Stem Cell Research, 2020, 48, 101934.	0.3	3
12	Burden of Illness in Adults With Hypophosphatasia: Data From the Global Hypophosphatasia Patient Registry. Journal of Bone and Mineral Research, 2020, 35, 2171-2178.	3.1	38
13	Establishment of variant free-iPSC (UOMi003-A) line from patient with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Stem Cell Research, 2020, 48, 101935.	0.3	0
14	Multigenerational case examples of hypophosphatasia: Challenges in genetic counseling and disease management. Molecular Genetics and Metabolism Reports, 2020, 25, 100661.	0.4	12
15	Induced pluripotent stem cell line UOMi002-A from a patient with Leigh syndrome with compound heterozygous mutations in the NDUFV1 gene. Stem Cell Research, 2020, 48, 101964.	0.3	8
16	Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres. Molecular Genetics and Metabolism Reports, 2020, 24, 100618.	0.4	2
17	Mass Spectrometry Evaluation of Biomarkers in the Vitreous Fluid in Gaucher Disease Type 3 with Disease Progression Despite Long-Term Treatment. Diagnostics, 2020, 10, 69.	1.3	0
18	Health Care for Mitochondrial Disorders in Canada: A Survey of Physicians. Canadian Journal of Neurological Sciences, 2019, 46, 717-726.	0.3	6

#	Article	IF	Citations
19	Efficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2735-2747.	1.8	46
20	Letter to the Editor: â€œEfficacy and Safety of Asfotase Alfa in Infants and Young Children With Hypophosphatasia: A Phase 2 Open-Label Studyâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3146-3147.	1.8	3
21	Health services use among children diagnosed with medium-chain acyl-CoA dehydrogenase deficiency through newborn screening: a cohort study in Ontario, Canada. Orphanet Journal of Rare Diseases, 2019, 14, 70.	1.2	9
22	ALPL mutations in adults with rheumatologic disorders and low serum alkaline phosphatase activity. Journal of Bone and Mineral Metabolism, 2019, 37, 893-899.	1.3	9
23	Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskeletal Disorders, 2019, 20, 80.	0.8	69
24	Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone, 2019, 121, 149-162.	1.4	99
25	Enzyme replacement therapy in perinatal hypophosphatasia: Case report of a negative outcome and lessons for clinical practice. Molecular Genetics and Metabolism Reports, 2018, 14, 22-26.	0.4	14
26	Newborn Screening for IKBKB Deficiency in Manitoba, Using Genetic Mutation Analysis. Journal of Clinical Immunology, 2018, 38, 742-744.	2.0	5
27	Does specialist physician supply affect pediatric asthma health outcomes?. BMC Health Services Research, 2018, 18, 247.	0.9	6
28	Caffeine is a risk factor for osteopenia of prematurity in preterm infants: a cohort study. BMC Pediatrics, 2018, 18, 9.	0.7	31
29	Type A Aortic Dissection, Apparent Mineralocorticoid Excess Syndrome, and Syndromic Aortic Root Dilatation. AACE Clinical Case Reports, 2017, 3, 291-293.	0.4	1
30	The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study. Orphanet Journal of Rare Diseases, 2016, 11, 12.	1.2	38
31	Asfotase Alfa Treatment Improves Survival for Perinatal and Infantile Hypophosphatasia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 334-342.	1.8	189
32	Identifying Nonâ€“Duchenne Muscular Dystrophyâ€“Positive and False Negative Results in Prior Duchenne Muscular Dystrophy Newborn Screening Programs. JAMA Neurology, 2016, 73, 111.	4.5	48
33	Asfotase alfa therapy for children with hypophosphatasia. JCI Insight, 2016, 1, e85971.	2.3	123
34	A novel CCBE1 mutation leading to a mild form of hennekam syndrome: case report and review of the literature. BMC Medical Genetics, 2015, 16, 28.	2.1	14
35	Hypophosphatasia. Pediatric Endocrinology Reviews, 2013, 10 Suppl 2, 380-8.	1.2	37
36	Cloacal exstrophy and related abdominal wall defects in Manitoba: Incidence and demographic factors. Clinical Genetics, 1985, 27, 241-251.	1.0	18